HSV-2 transmission

被引:35
作者
Sacks, SL
Griffiths, PD
Corey, L
Cohen, C
Cunningham, A
Dusheiko, GM
Self, S
Spruance, S
Stanberry, LR
Wald, A
Whitley, RJ
机构
[1] Univ Alabama, Birmingham, AL USA
[2] Viridae, Vancouver, BC, Canada
[3] UCL Royal Free & Univ Coll Med Sch, Dept Virol, London, England
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Westmead Millennium Inst, Westmead, NSW, Australia
[7] UCL Royal Free Hosp, Acad Dept Med, London NW3 2QG, England
[8] Univ Utah, Sch Med, Salt Lake City, UT 84112 USA
[9] Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77550 USA
[10] Univ Texas, Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77550 USA
[11] Univ Washington, Seattle, WA 98195 USA
关键词
HSV-2; transmission; neonatal HSV-2; antiviral; shedding;
D O I
10.1016/j.antiviral.2004.06.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A number of important risk factors for the acquisition of HSV-2 have been established including female gender, black or Hispanic ethnic origin. HIV infection, age, and increased number of sexual partners. Transmission is influenced by a number of biological factors such as sexual behavior, use of condoms, duration of relationships, and knowledge of a partner's serologic status. Vertical transmission (transmission of HSV from mother to neonate) is potentially life-threatening; neonatal HSV infection is associated with significant morbidity and mortality. The valaciclovir transmission study provides evidence that an antiviral agent can interrupt the transmission of a viral sexually transmitted disease between serologically discordant sexual partners. This review explores the importance of the cofactors that affect transmission, and makes recommendations on considerations for the prophylactic use of antiviral agents for the prevention of transmission in other patient populations. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:S27 / S35
页数:9
相关论文
共 23 条
[11]   RISK-FACTORS FOR THE SEXUAL TRANSMISSION OF GENITAL HERPES [J].
MERTZ, GJ ;
BENEDETTI, J ;
ASHLEY, R ;
SELKE, SA ;
COREY, L .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (03) :197-202
[12]  
Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19
[13]   PERINATAL RISK ASSOCIATED WITH MATERNAL GENITAL HERPES SIMPLEX VIRUS INFECTION [J].
NAHMIAS, AJ ;
JOSEY, WE ;
NAIB, ZM ;
FREEMAN, MG ;
FERNANDEZ, RJ ;
WHEELER, JH .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1971, 110 (06) :825-+
[14]   LOW-RISK OF HERPES-SIMPLEX VIRUS-INFECTIONS IN NEONATES EXPOSED TO THE VIRUS AT THE TIME OF VAGINAL DELIVERY TO MOTHERS WITH RECURRENT GENITAL HERPES-SIMPLEX VIRUS-INFECTIONS [J].
PROBER, CG ;
SULLENDER, WM ;
YASUKAWA, LL ;
AU, DS ;
YEAGER, AS ;
ARVIN, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (05) :240-244
[15]   Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment [J].
Reiff-Eldridge, R ;
Heffner, CR ;
Ephross, SA ;
Tennis, PS ;
White, AD ;
Andrews, EB .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (01) :159-163
[16]   Acyclovir suppression to prevent cesarean delivery after first-episode genital Herpes [J].
Scott, LL ;
Sanchez, PJ ;
Jackson, GL ;
Zeray, F ;
Wendel, GD .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (01) :69-73
[17]   Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: A systematic review [J].
Sheffield, JS ;
Hollie, LM ;
Hill, JB ;
Stuart, GS ;
Wendel, GD .
OBSTETRICS AND GYNECOLOGY, 2003, 102 (06) :1396-1403
[18]  
Smith JR, 1998, BRIT J OBSTET GYNAEC, V105, P255
[19]   Glycoprotein-D-adjuvant vaccine to prevent genital herpes [J].
Stanberry, LR ;
Spruance, SL ;
Cunningham, AL ;
Bernstein, DI ;
Mindel, A ;
Sacks, S ;
Tyring, S ;
Aoki, FY ;
Slaoui, M ;
Denis, M ;
Vandepapeliere, P ;
Dubin, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1652-1661
[20]   ACYCLOVIR IN LATE PREGNANCY TO PREVENT NEONATAL HERPES-SIMPLEX [J].
STRAYPEDERSEN, B .
LANCET, 1990, 336 (8717) :756-756